Roche Acquires Biopharm Company lnflazome for $443 MBy
Roche has acquired Inflazome, a Dublin, Ireland-based company developing inflammasome inhibitors for treating chronic inflammatory diseases, for EUR 380 million ($443 million) with Inflazome shareholders also eligible to receive additional milestone payments.
The acquisition gives Roche full rights to Inflazome’s entire portfolio, which is composed of clinical and preclinical orally available small-molecule NLRP3 inhibitors. Activation of the NLRP3 inflammasome in the body is implicated in many diseases caused by chronic, uncontrolled inflammation, according to information from Inflazome. Roche says it intends to further develop NLRP3 inhibitors across a variety of indications.